Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Targeting Menin in T-Lineage Acute Lymphoblastic Leukemia

Kathryn Kimi Shimamoto, Arda Arda Karaoglu, Zachary Chan, Giorgia Giordano, Bartholomew Eisfelder, Jason Xiaojun Cheng, Hamed Youshanlouei, Syed Shah, Anand Ashwin Patel, Adam S. Duvall, Francis Burrows, Linda Kessler, Michael W Drazer, Olatoyosi Odenike, Michael J. Thirman, Wendy Stock, Caner Saygin

Blood (2024) 144 (Supplement 1): 1452.

https://doi.org/10.1182/blood-2024-201741

Published: 2024

Journal Articles

Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia

Sandhya Dhiman, Md. Hafiz Uddin, Vikram Dhillon, Jeff Justin Aguilar, Amro Aboukameel, Husain Khan, Sahar Bannoura, Jay Yang, Gregory Dyson, Steven Buck, Asfar Azmi, Lisa Polin, Francis Burrows, Linda Kessler, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 2768.

https://doi.org/10.1182/blood-2024-206075

Published: 2024

Journal Articles

The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax

Johanna Rausch, Margarita M. Dzama, Nadezda Dolgikh, Hanna Stiller, Stephan Bohl, Catharina Lahrmann, Kerstin Kunz, Linda Kessler, Hakim Echchannaoui, Chun-Wei David Chen, Thomas Kindler, Francis Burrows, Matthias Theobald, Daniel Sasca, Scott A. Armstrong, Michael Kuehn

Blood (2022) 140 (Supplement 1): 6226–6227.

https://doi.org/10.1182/blood-2022-167566

Published: 2022

Journal Articles

Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A -Rearranged Acute Lymphoblastic Leukemia

Catherine D Falkenstein, Lisa M Niswander, Linda Kessler, Blake Tomkinson, Francis Burrows, Sarah K Tasian

Blood (2022) 140 (Supplement 1): 3491–3492.

https://doi.org/10.1182/blood-2022-157225

Published: 2022

Journal Articles

Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models

John A. Davis, Warren C. Fiskus, Naval Daver, Christopher Peter Mill, Christine Birdwell, Arnold Salazar, Kevin Philip, Tapan M. Kadia, Courtney D. DiNardo, Mollie Leoni, Francis Burrows, Kapil N. Bhalla

Blood (2021) 138 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2021-149831

Published: 2021

Journal Articles

Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Eunice S. Wang, MD, Jessica K. Altman, MD, Kristen Pettit, Stephane De Botton, Roland P Walter, MDPhD, Pierre Fenaux, MD PhD, Francis Burrows, PhD, Blake E. Tomkinson, PhDMBA, Bridget Martell, MA, MD, Amir T. Fathi, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134942

Published: 2020

Journal Articles

Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines

Ruth Alonso Alonso, PhD, Rufino Mondejar García, PhD, Jose Pedro Vaqué Díez, PhD, Nuria García Díaz, PhDcandidate, Cristina Pérez Menéndez, PhD, Francis Burrows, PhD, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD, Miguel A. Piris, PhD MD

Blood (2018) 132 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2018-99-118291

Published: 2018

Journal Articles

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma

Thomas E Witzig, MD, Lubomir Sokol, MD PhD, Eric Jacobsen, MD, Ranjana H. Advani, MD, Francine M Foss, MD, Rufino Mondejar, PhD, Miguel Angel Piris, PhDMD, James Bolognese, PhD, Francis Burrows, PhD, Linda Kessler, BA, Karen Bracken, MHS, Vishnu Mishra, PhD, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD

Blood (2017) 130 (Supplement 1): 2788.

https://doi.org/10.1182/blood.V130.Suppl_1.2788.2788

Published: 2017

Journal Articles

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Andrew Spencer, Simon Harrison, MD, Francis Burrows, Paul Mainwaring, MD, Timothy Price, MD, Michael J Millward, MD, Peeter Padrik, MD, Craig Underhill, MD, Paul Cannell, MD, Steven D Reich, MD, Mohit Trikha, PhD

Blood (2015) 126 (23): 5375.

https://doi.org/10.1182/blood.V126.23.5375.5375

Published: 2015

Journal Articles

In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents

Zeena Salman, MD MPH, Jeanne P. De Leon, Eric J. Feldman, MD, Francis Burrows, PhD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2014) 124 (21): 3765.

https://doi.org/10.1182/blood.V124.21.3765.3765

Published: 2014

Journal Articles

Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma

Katelyn G. Barnhart, Shannon M. Matulis, Ph.D., Sadae Hitosugi, MS, Cathy Sharp, R.N., Francis Burrows, PhD, Ajay K. Nooka, MD, MPH, Jonathan L. Kaufman, MD, Sagar Lonial, M.D., Lawrence H. Boise, PhD

Blood (2013) 122 (21): 3171.

https://doi.org/10.1182/blood.V122.21.3171.3171

Published: 2013

Journal Articles

Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents

Monica L. Guzman, PhD, Wen Xie, MS, Jeanne P. De Leon, Francis Burrows, PhD, Eric J. Feldman, MD, Gail J. Roboz, MD

Blood (2013) 122 (21): 3892.

https://doi.org/10.1182/blood.V122.21.3892.3892

Published: 2013

Journal Articles

Effectiveness of Transcriptional CDK Inhibitors in Targeting Non-Proliferating CD34+CD38- AML Cells,

Monica Pallis, PhD, Francis Burrows, PhD, Abigail Whittall, B Med Sci, Claire Seedhouse, PhD, Nicholas Boddy, B Med Sci, Nigel H. Russell, MD

Blood (2011) 118 (21): 3482.

https://doi.org/10.1182/blood.V118.21.3482.3482

Published: 2011

Journal Articles

Antimyeloma Action of the Multikinase Inhibitor TG02

Stela Álvarez-Fernández, Susana Hernández-García, Xi Chen, Enrique M. Ocio, Jr., MD, PhD, Bruno Paiva, Kay R. Meshow, Lynn A. Cheatham, Francis Burrows, PhD, Jesús F. San Miguel, Sr., MD, PhD, Atanasio Pandiella, Sr., MD, PhD

Blood (2010) 116 (21): 4062.

https://doi.org/10.1182/blood.V116.21.4062.4062

Published: 2010

Journal Articles

The Multi-Kinase Inhibitor TG02 targets CD34+CD38-CD123+ AML Cells

Monica Pallis, PhD, Francis Burrows, PhD, Nigel H. Russell, MD

Blood (2010) 116 (21): 1823.

https://doi.org/10.1182/blood.V116.21.1823.1823

Published: 2010

Journal Articles

The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells.

Alessandra Ferrajoli, MD, Yongtao Wang, MD, Susan M. O’Brien, MD, Stefan H. Faderl, MD, David M. Harris, BS, Quin Van, BS, Inbal Hallevi, PhD, Zhiming Liu, BS, Patricia E. Koch, MS, John Sensintaffar, MS, Francis Burrows, PhD, Hagop M. Kantarjian, MD, Michael J. Keating, MB, BS, Zeev Estrov, MD

Blood (2007) 110 (11): 2784.

https://doi.org/10.1182/blood.V110.11.2784.2784

Published: 2007

NARROW

Targeting Menin in T-Lineage Acute Lymphoblastic Leukemia

Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia

The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax

Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A -Rearranged Acute Lymphoblastic Leukemia

Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models

Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents

Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma

Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents

Effectiveness of Transcriptional CDK Inhibitors in Targeting Non-Proliferating CD34+CD38- AML Cells,

Antimyeloma Action of the Multikinase Inhibitor TG02

The Multi-Kinase Inhibitor TG02 targets CD34+CD38-CD123+ AML Cells

The Synthetic Hest Shock Protein (Hsp) 90 Inhibitor EC141 Induces Degradation of the Bcr-Abl p190 Protein and Apoptosis of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only